These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 30934376)

  • 1. Low-risk thyroid carcinoma: when is the treatment worse than the disease?
    Potenza M; Mechanick JI
    Expert Rev Endocrinol Metab; 2009 Jan; 4(1):5-7. PubMed ID: 30934376
    [No Abstract]   [Full Text] [Related]  

  • 2. A diffuse sclerosing variant of papillary thyroid carcinoma: clinical and pathologic features and outcomes of 34 consecutive cases.
    Regalbuto C; Malandrino P; Tumminia A; Le Moli R; Vigneri R; Pezzino V
    Thyroid; 2011 Apr; 21(4):383-9. PubMed ID: 21309722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension.
    Randolph GW; Duh QY; Heller KS; LiVolsi VA; Mandel SJ; Steward DL; Tufano RP; Tuttle RM;
    Thyroid; 2012 Nov; 22(11):1144-52. PubMed ID: 23083442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors and the therapeutic strategy for patients with bone metastasis from differentiated thyroid carcinoma.
    Orita Y; Sugitani I; Matsuura M; Ushijima M; Tsukahara K; Fujimoto Y; Kawabata K
    Surgery; 2010 Mar; 147(3):424-31. PubMed ID: 20176243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Surgical treatment of differentiated thyroid carcinoma].
    Xu HZ
    Hua Xi Yi Ke Da Xue Xue Bao; 1989 Mar; 20(1):112-4. PubMed ID: 2793133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical presentations and outcomes of surgical treatment of follicular variant of the papillary thyroid carcinomas.
    Chang HY; Lin JD; Chou SC; Chao TC; Hsueh C
    Jpn J Clin Oncol; 2006 Nov; 36(11):688-93. PubMed ID: 17000702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical guideline for management of patients with low risk differentiated thyroid carcinoma].
    Díez JJ; Oleaga A; Álvarez-Escolá C; Martín T; Galofré JC;
    Endocrinol Nutr; 2015; 62(6):e57-72. PubMed ID: 25857691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic indicators in well-differentiated thyroid carcinoma when controlling for stage and treatment.
    Krook KA; Fedewa SA; Chen AY
    Laryngoscope; 2015 Apr; 125(4):1021-7. PubMed ID: 25583017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of second primary malignancy on outcomes of differentiated thyroid carcinoma.
    Lang BH; Lo CY; Wong IO; Cowling BJ
    Surgery; 2010 Dec; 148(6):1191-6; discussion 1196-7. PubMed ID: 21134551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Invasive well-differentiated thyroid carcinoma: effect of treatment modalities on outcome.
    Segal K; Shpitzer T; Hazan A; Bachar G; Marshak G; Popovtzer A
    Otolaryngol Head Neck Surg; 2006 May; 134(5):819-22. PubMed ID: 16647541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of outcome for patients with differentiated and aggressive thyroid carcinoma.
    Marchesi M; Biffoni M; Biancari F; Berni A; Campana FP
    Eur J Surg Suppl; 2003 Jul; (588):46-50. PubMed ID: 15200043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrence pattern after conservative surgery for papillary thyroid carcinoma.
    Kobayashi K; Takenouchi S; Mitani H; Yoshida T
    Auris Nasus Larynx; 2014 Dec; 41(6):548-51. PubMed ID: 24976169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Expression of protein p53: the marker of low neoplastic cell differentiation in thyroid carcinoma].
    Szybiński P; Nowak W; Stachura J; Nowak K; Przybylik-Mazurek E; Buziak-Bereza M
    Wiad Lek; 2001; 54 Suppl 1():88-94. PubMed ID: 12182067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pediatric thyroid carcinoma: incidence and outcomes in 1753 patients.
    Hogan AR; Zhuge Y; Perez EA; Koniaris LG; Lew JI; Sola JE
    J Surg Res; 2009 Sep; 156(1):167-72. PubMed ID: 19631341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does microscopically involved margin increase disease recurrence after curative surgery in papillary thyroid carcinoma?
    Lang BH; Shek TW; Wan KY
    J Surg Oncol; 2016 May; 113(6):635-9. PubMed ID: 26843438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of survival rates between papillary and follicular thyroid carcinomas among 36,725 patients.
    Oyer SL; Fritsch VA; Lentsch EJ
    Ann Otol Rhinol Laryngol; 2014 Feb; 123(2):94-100. PubMed ID: 24574464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors in patients with Hürthle cell neoplasms of the thyroid.
    Lopez-Penabad L; Chiu AC; Hoff AO; Schultz P; Gaztambide S; Ordoñez NG; Sherman SI
    Cancer; 2003 Mar; 97(5):1186-94. PubMed ID: 12599224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic factors in papillary microcarcinoma with emphasis on histologic subtyping: a clinicopathologic study of 148 cases.
    Ghossein R; Ganly I; Biagini A; Robenshtok E; Rivera M; Tuttle RM
    Thyroid; 2014 Feb; 24(2):245-53. PubMed ID: 23745671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk-adapted management of papillary thyroid carcinoma according to our own risk group classification system: is thyroid lobectomy the treatment of choice for low-risk patients?
    Ebina A; Sugitani I; Fujimoto Y; Yamada K
    Surgery; 2014 Dec; 156(6):1579-88; discussion 1588-9. PubMed ID: 25262223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of BRAF v600e immunocytochemistry on FNA direct smears of papillary thyroid carcinoma.
    Wobker SE; Kim LT; Hackman TG; Dodd LG
    Cancer Cytopathol; 2015 Sep; 123(9):531-9. PubMed ID: 26080065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.